Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 25, 2015 9:34 AM ET

Healthcare Equipment and Supplies

Company Overview of Tandem Diabetes Care, Inc.

Company Overview

Tandem Diabetes Care, Inc., a medical device company, focuses on the design, development, and commercialization of various products for people with insulin-dependent diabetes in the United States. The company offers t:slim insulin delivery system that comprises t:slim pump, its disposable insulin cartridge, and an infusion set; t:connect diabetes management application, a PC and Mac-compatible cloud-based data management application that provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and t:flex insulin delivery system that includes 480-unit disposable insulin cartridge and ...

11045 Roselle Street

San Diego, CA 92121

United States

Founded in 2006

437 Employees



Key Executives for Tandem Diabetes Care, Inc.

Chief Executive Officer, President and Director
Age: 62
Total Annual Compensation: $532.7K
Chief Financial Officer and Treasurer
Age: 48
Total Annual Compensation: $362.6K
Chief Operating Officer and Executive Vice President
Age: 59
Total Annual Compensation: $347.1K
Chief Commercial Officer and Executive Vice President
Age: 63
Total Annual Compensation: $347.1K
Chief Administrative Officer
Age: 35
Total Annual Compensation: $275.2K
Compensation as of Fiscal Year 2014.

Tandem Diabetes Care, Inc. Key Developments

Tandem Diabetes Care, Inc. Commences Shipping t:slim Insulin Pump with Updated Software

Tandem Diabetes Care, Inc. commenced shipments of t:slim Pumps featuring enhanced software. The updated software, based on customer and healthcare provider feedback, includes an expansion of the reverse correction function, the ability to enter a manual bolus directly in the suggested bolus window, off-pump cartridge filling, and other features to enhance convenience and flexibility. Tandem is actively working on a project to provide current t:slim Pump users the ability to update their pump software remotely, similar to other modern consumer devices. The company plans to submit a filing for this remote update capability to the U.S. Food and Drug Administration later in 2015.

Tandem Diabetes Care, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year Ending December 31, 2015

Tandem Diabetes Care, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $18,465,000 or $0.78 per basic and diluted share on sales of $17,889,000 against net loss of $23,613,000 or $2.14 per basic and diluted share on sales of $10,245,000 a year ago. Operating loss of $17,502,000 compared to $16,463,000 a year ago. Loss before taxes of $18,394,000 compared to $23,613,000 a year ago. For the full year, the company reported net loss of $79,524,000 or $3.42 per basic and diluted share on sales of $49,722,000 against net loss of $63,139,000 or $21.46 per basic and diluted share on sales of $29,007,000 a year ago. Operating loss of $75,664,000 compared to $49,434,000 a year ago. Loss before taxes of $79,453,000 compared to $63,139,000 a year ago. For the year ending December 31, 2015, the company is providing its guidance as follows: sales are estimated to be in the range of $70.0 million to $75.0 million, which includes $1.0 million to $3.0 million of t:flex Insulin Pump sales, and operating margin is estimated to be in the range of negative 100% to negative 110%, which includes approximately $13.0 million to $14.0 million in non-cash stock-based compensation expense.

Tandem Diabetes Care, Inc. to Report Q4, 2014 Results on Feb 24, 2015

Tandem Diabetes Care, Inc. announced that they will report Q4, 2014 results After-Market on Feb 24, 2015

Similar Private Companies By Industry

Company Name Region
Vanguard Home Medical Equipment United States
Medivators Inc. United States
Nexus CMF, L.L.C. United States
Jaya Medical Supplies, Inc. United States
USGI Medical, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tandem Diabetes Care, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at